Hospital and ventilator acquired pneumonia Full details for md exam answer 15 marks

Reading File

Finding Sources

Reading File

I now have comprehensive information from multiple authoritative textbooks. Let me compile the full MD exam answer.

Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP)

1. DEFINITIONS

Hospital-Acquired Pneumonia (HAP): Pneumonia developing ≥48 hours after hospital admission in a patient who was not intubated at the time of onset.

Ventilator-Associated Pneumonia (VAP): Pneumonia occurring ≥3 days (≥48–72 hours) after endotracheal intubation and commencement of mechanical ventilation.

HAP is further subdivided into:

VAP — in mechanically ventilated patients
Non-ventilator HAP (NV-HAP) — in non-ventilated hospitalised patients

— Goldman-Cecil Medicine, p. 1000; Current Surgical Therapy 14e, p. 1626

2. EPIDEMIOLOGY

Parameter	Data
Incidence	5–10 cases per 1000 hospital admissions
Most common cause of hospital-acquired infection	2nd (after UTI)
VAP incidence	~3.5% of ventilated patients; 16% of those ventilated >1 day
NV-HAP incidence	~0.5% of non-ventilated patients
Overall VAP mortality	~13%
Crude mortality (HAP/VAP combined)	15–30%
Median length of stay (HAP patients)	15–30 days vs. ~5 days in non-affected patients

Most hospital-acquired pneumonia is NV-HAP (more non-ventilated patients overall).
Incidence rises with age; predominantly affects medical, surgical, oncology, and neurology services.

— Goldman-Cecil Medicine, p. 1000; Current Surgical Therapy 14e, p. 1626

3. PATHOGENESIS / PATHOPHYSIOLOGY

HAP and VAP primarily result from microaspiration or macroaspiration of oropharyngeal and gastric secretions when perturbations of the oral microbiome permit pathogenic organisms to proliferate.

Key mechanisms:

Colonisation of the oropharynx/stomach with pathogenic organisms (gram-negatives, S. aureus) in hospitalised patients
Aspiration of colonised secretions into the lower respiratory tract — chemical analyses confirm gastrin/pepsin in up to 2/3 of intubated patients' tracheal aspirates
Impaired host defences — sedation, endotracheal tube bypassing mucociliary clearance, cough suppression
Biofilm formation on endotracheal tubes — reservoir for recurrent seeding
Haematogenous spread (less common)

The result is heterogeneous, scattered areas of bronchopneumonia at various stages, some with organisms and some without — confirmed on microscopic/microbial autopsy evaluation.

— Goldman-Cecil Medicine, p. 1000

4. MICROBIOLOGY / CAUSATIVE ORGANISMS

Common Pathogens (VAP & HAP):

Organism	Approximate Frequency
Staphylococcus aureus (inc. MRSA)	30–40%
Pseudomonas aeruginosa	15–20%
Klebsiella pneumoniae	~10%
Enterobacter spp.	5–10%
Escherichia coli	5–10%
Haemophilus influenzae	~5%
Streptococcus spp.	~5%
Acinetobacter baumannii	3–10%

Drug resistance is a major concern:

50% of S. aureus are MRSA
28–35% of Pseudomonas are resistant to cefepime
56–61% of Acinetobacter are resistant to carbapenems
19–29% of gram-negative bacilli resistant to piperacillin-tazobactam

Viral aetiology: Up to 20–25% of HAP may be due to respiratory viruses (rhinovirus, influenza, parainfluenza, metapneumovirus, coronaviruses). Another 15% involve viral-bacterial co-infection.

— Goldman-Cecil Medicine, p. 1001; Current Surgical Therapy 14e, p. 1626

5. RISK FACTORS

Risk Factors for HAP (General):

Impaired consciousness / sedation
Dysphagia
Enteral feeding (oral or nasogastric tube)
Prolonged hospitalisation
Immunosuppression
Older age

Risk Factors for VAP:

Mechanical ventilation >1 day
Supine positioning
Reintubation
Nasogastric tube
H2 blockers / PPIs (↑ gastric pH → bacterial overgrowth)
Prior broad-spectrum antibiotics

Risk Factors for MDR Pathogens in VAP:

Prior IV antibiotic use within 90 days
Septic shock at time of VAP
ARDS preceding VAP
≥5 days in hospital before VAP onset
Acute renal replacement therapy (RRT) before VAP onset

Risk Factors for MDR Pathogens in HAP:

Prior IV antibiotic use within 90 days

— Current Surgical Therapy 14e, p. 1626–1627; Goldman-Cecil Medicine, p. 1000

6. CLINICAL FEATURES

Symptoms typically appear after a median 4–7 days from hospital admission. Cardinal features include:

Fever (>38°C)
Tachypnoea, increased respiratory secretions
Purulent sputum / secretions
Leukocytosis (WBC ≥12,000)
Decline in SpO₂ / worsening oxygenation
New radiographic infiltrates on chest X-ray
Positive lower respiratory tract cultures

None of these features is individually sensitive or specific for HAP/VAP.

Diagnostic accuracy of individual signs (meta-analysis, 25 studies, n=1639):

Sign	Sensitivity	Specificity
Fever	66%	54%
Purulent secretions	77%	39%
Leukocytosis	64%	59%
New CXR infiltrate	89%	26%
Endotracheal aspirate ≥10⁴ CFU/mL	76%	68%
BAL ≥10⁴ CFU/mL	71%	80%

The combination of radiographic infiltrate + any two of fever, purulent secretions, leukocytosis: sensitivity 69%, specificity 75%. Adding all three to infiltrate: specificity rises to 92% but sensitivity falls to 23%.

— Goldman-Cecil Medicine, p. 1000–1001

7. DIAGNOSIS

Diagnosis is subjective — experienced clinicians often disagree. A multi-modal approach is required.

Clinical Scoring — Clinical Pulmonary Infection Score (CPIS):

Used to quantify clinical suspicion; score ≥6 suggests pneumonia.

Microbiological Investigations:

Endotracheal aspirate (ETA) — for semiquantitative culture; preferred over invasive sampling in VAP (no outcome difference, quicker, fewer resources needed)
Sputum culture — for HAP in non-ventilated patients (expectoration, induction, nasotracheal suctioning)
Bronchoalveolar lavage (BAL) — quantitative, threshold ≥10⁴ CFU/mL; BAL positive in only ~1/3 of suspected VAP; can worsen hypoxia in ARDS
Blood cultures — should be drawn in all cases; bacteraemia in ~10–15% of HAP/VAP; 25% of positive blood cultures point to non-pulmonary sources
MRSA nasal PCR screen — negative result in low-prevalence hospitals allows withholding of MRSA coverage

Biomarkers:

Procalcitonin — sensitivity 60–70%, specificity 24–80%; not recommended for routine diagnosis; useful to guide de-escalation (safe to discontinue antibiotics when PCT drops to normal or ≤20% of peak)

Imaging:

Chest X-ray — new/progressive infiltrate (non-specific; also seen in pulmonary oedema, atelectasis, PE)
CT chest (with contrast) — better differentiates pneumonic consolidation from atelectasis, pulmonary oedema, pneumonitis; also identifies complications (abscess, empyema)

VAE (Ventilator-Associated Events) Surveillance Algorithm (CDC/NHSN):

Category	Criteria
VAC (Ventilator-Assoc. Condition)	After ≥2 days of stability: FiO₂ ↑≥0.20 or PEEP ↑≥3 cmH₂O sustained ≥2 days
IVAC (Infection-related VAC)	VAC + Temperature >38°C or <36°C or WBC ≥12 or ≤4 + new antibiotic continued ≥4 days
Possible VAP	IVAC + purulent secretions (≥25 neutrophils, ≤10 squamous epithelial cells) or positive culture
Probable VAP	Stricter microbiological criteria

Note: VAC/IVAC are for public reporting; VAP rates are for internal quality improvement.

— Goldman-Cecil Medicine, p. 1000–1001; Current Surgical Therapy 14e, p. 1626

8. TREATMENT

Principles:

Obtain cultures first (ETA/sputum), then start empiric antibiotics immediately — do not delay
Tailor to local antibiogram and patient's MDR risk factors
De-escalate to narrowest spectrum once culture results available
Duration: 7 days (IDSA/ATS recommendation) — longer courses lead to more MDR organisms

Empiric Antibiotic Strategy:

Group A — No MDR risk factors, early onset:

Narrow-spectrum monotherapy
Options: Ceftriaxone, Ampicillin-sulbactam, Ertapenem, Levofloxacin, or Moxifloxacin
Covers: S. pneumoniae, H. influenzae, MSSA, sensitive gram-negative bacilli (E. coli, Klebsiella, Proteus, Serratia, Enterobacter)

Group B — MDR risk factors OR high MRSA prevalence:

Add MRSA coverage (Vancomycin or Linezolid) if MRSA prevalence >10–20% or patient has MRSA risk factors
Add dual antipseudomonal coverage if MDR risk factors or gram-negative resistance >10% on antibiogram:
- Antipseudomonal β-lactam: piperacillin-tazobactam, cefepime, ceftazidime, imipenem, or meropenem
- Plus aminoglycoside or antipseudomonal fluoroquinolone (ciprofloxacin or high-dose levofloxacin)

High mortality risk (septic shock / need for MV):

Combination broad-spectrum therapy mandatory
Add anti-MRSA agent + two antipseudomonal agents

Organism-Specific Definitive Therapy:

Organism	Drug of Choice
MSSA	Oxacillin, nafcillin, or cefazolin
MRSA	Vancomycin (trough 15–20 µg/mL) or Linezolid (preferred in renal insufficiency)
Pseudomonas	Monotherapy once susceptibilities known; dual therapy if septic shock persists
Acinetobacter	Carbapenem (imipenem/meropenem); colistin/polymyxin if carbapenem-resistant
Carbapenem-resistant GNBs	Ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol

Special Notes:

Aminoglycosides — avoid as monotherapy (poor lung penetration, nephrotoxicity, ototoxicity); use once-daily dosing at 7 mg/kg if used
Linezolid vs. vancomycin in MRSA VAP — linezolid preferred in renal insufficiency and with other nephrotoxic drugs
Daptomycin — inactivated by pulmonary surfactant; do not use for pneumonia
Telavancin — associated with increased mortality in HAP/VAP; avoid
Aztreonam — reserved as a second-line agent; no cross-allergenicity with penicillins/cephalosporins (except ceftazidime)
Extended/continuous β-lactam infusions — enhance bactericidal activity by maximising time above MIC
Vancomycin monitoring — AUC₀₋₂₄-guided dosing preferred over trough-only monitoring

— Current Surgical Therapy 14e, p. 1627–1628; Fishman's Pulmonary Diseases, p. 2205; Goldman-Cecil Medicine, p. 1001

9. PREVENTION

The most important preventive step is avoiding tracheal intubation wherever safe.

VAP Prevention Bundle (ICU):

Avoid intubation — use high-flow nasal oxygen or non-invasive positive pressure ventilation (NIV/CPAP) as alternatives
Semi-recumbent positioning — head-of-bed elevation 30–45°
Minimise sedation — use propofol or dexmedetomidine (rather than benzodiazepines) to allow spontaneous breathing trials
Daily spontaneous breathing trials — earliest possible extubation
Oral decontamination — chlorhexidine oral care
Subglottic secretion drainage — specialised endotracheal tubes with suction ports above the cuff
Early mobilisation
Avoid unnecessary ventilator circuit changes
Cuff pressure maintenance — prevent aspiration around the cuff
Modification of endotracheal tubes/cuffs — to reduce microbial colonisation and biofilm formation (none has yet consistently reduced mortality)

— Goldman-Cecil Medicine, p. 1001–1002; Current Surgical Therapy 14e

10. PROGNOSIS

Crude mortality: 15–30% (VAP and NV-HAP similar)
Median length of stay: 15–30 days (vs. ~5 days for unaffected patients)
Eliminating VAP alone would reduce overall ICU mortality by only ~2% (underlying illness contributes heavily)
NV-HAP may increase mortality by 2-fold or more compared with matched controls
Mortality appears similar regardless of viral, bacterial, or mixed aetiology

— Goldman-Cecil Medicine, p. 1002

SUMMARY TABLE

Feature	HAP	VAP
Definition	Pneumonia ≥48h after admission, non-ventilated	Pneumonia ≥3 days after intubation
Incidence	~0.5% of non-ventilated	~3.5% of ventilated (16% if >1 day ventilated)
Key pathogens	S. aureus, Pseudomonas, gram-neg bacilli	Same
Diagnosis	Clinical + CXR + ETA/sputum culture	Clinical + CXR + ETA/BAL culture + NHSN VAE algorithm
Empiric Rx	Narrow (no MDR) vs. Broad (MDR risk)	Broad ± MRSA coverage
Duration	7 days	7 days
Key prevention	Hygiene, mobilisation, early discharge	Avoid intubation, VAP bundle
Mortality	15–30%	15–30% (13% overall)

Sources: Goldman-Cecil Medicine International Edition pp. 1000–1002 | Current Surgical Therapy 14e pp. 1626–1628 | Fishman's Pulmonary Diseases and Disorders p. 2205

This is a shared conversation. Sign in to Orris to start your own chat.